The impact of low forced vital capacity on behavior restrictions in a population with airflow obstruction.
Airflow obstruction (AO)
forced vital capacity (FVC)
physical activity
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
entrez:
11
6
2019
pubmed:
11
6
2019
medline:
11
6
2019
Statut:
ppublish
Résumé
Recent studies have suggested that low forced vital capacity (FVC) is related to respiratory symptoms with various comorbid conditions that eventually lead to physical inactivity and may be applied to subjects with airflow obstruction (AO). Therefore, this study aimed to evaluate the association between low FVC and behavior restrictions in subjects with AO. A cross-sectional study was performed using data from the Korea National Health and Nutrition Survey conducted between 2007 and 2015. Participants aged 40 to 79 years with spirometry-defined AO (pre-bronchodilator forced expiratory volume in one second/FVC <70%) were analyzed to evaluate the association between low FVC (defined as FVC <80% predicted) and behavior restrictions. A total of 3,345 participants with AO were included. The proportion of subjects with low FVC varied widely according to severity of airflow limitation (0.9%, 35.5%, and 85.1% in the mild, moderate, and severe-to-very-severe AO groups, respectively). Compared to the moderate AO group with normal FVC, those with low FVC were more likely to be older, to be never- or ex-smokers, to have larger waist size with higher body mass index, and to have comorbidities such as diabetes, hypertension, dyslipidemia, and osteoporosis. Low FVC was independently associated with behavior restrictions [adjusted prevalence ratio (aPR), 1.72; 95% confidence interval (CI), 1.43-2.06] among all participants with AO, and this was most prominent in those with moderate AO (aPR, 1.65; 95% CI, 1.27-2.13). In subjects with moderate AO, low FVC was independently associated with behavior restrictions even after adjusting for confounding factors.
Sections du résumé
BACKGROUND
BACKGROUND
Recent studies have suggested that low forced vital capacity (FVC) is related to respiratory symptoms with various comorbid conditions that eventually lead to physical inactivity and may be applied to subjects with airflow obstruction (AO). Therefore, this study aimed to evaluate the association between low FVC and behavior restrictions in subjects with AO.
METHODS
METHODS
A cross-sectional study was performed using data from the Korea National Health and Nutrition Survey conducted between 2007 and 2015. Participants aged 40 to 79 years with spirometry-defined AO (pre-bronchodilator forced expiratory volume in one second/FVC <70%) were analyzed to evaluate the association between low FVC (defined as FVC <80% predicted) and behavior restrictions.
RESULTS
RESULTS
A total of 3,345 participants with AO were included. The proportion of subjects with low FVC varied widely according to severity of airflow limitation (0.9%, 35.5%, and 85.1% in the mild, moderate, and severe-to-very-severe AO groups, respectively). Compared to the moderate AO group with normal FVC, those with low FVC were more likely to be older, to be never- or ex-smokers, to have larger waist size with higher body mass index, and to have comorbidities such as diabetes, hypertension, dyslipidemia, and osteoporosis. Low FVC was independently associated with behavior restrictions [adjusted prevalence ratio (aPR), 1.72; 95% confidence interval (CI), 1.43-2.06] among all participants with AO, and this was most prominent in those with moderate AO (aPR, 1.65; 95% CI, 1.27-2.13).
CONCLUSIONS
CONCLUSIONS
In subjects with moderate AO, low FVC was independently associated with behavior restrictions even after adjusting for confounding factors.
Identifiants
pubmed: 31179073
doi: 10.21037/jtd.2019.03.77
pii: jtd-11-04-1316
pmc: PMC6531733
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1316-1324Déclaration de conflit d'intérêts
Conflicts of Interest: HY Park has received lecture fees from AstraZeneca, Novartis, and Boehringer-Ingelheim. The other authors have no conflicts of interest to declare.
Références
Thorax. 2003 Feb;58(2):100-5
pubmed: 12554887
Am J Respir Crit Care Med. 2005 May 1;171(9):972-7
pubmed: 15665324
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Chest. 2006 Mar;129(3):536-44
pubmed: 16537849
Proc Am Thorac Soc. 2006 Apr;3(2):176-9
pubmed: 16565428
Thorax. 2006 Sep;61(9):772-8
pubmed: 16738033
Am J Respir Crit Care Med. 2007 Mar 1;175(5):458-63
pubmed: 17158282
Ann Epidemiol. 2008 Oct;18(10):775-83
pubmed: 18708291
Am J Respir Crit Care Med. 2009 Mar 15;179(6):509-16
pubmed: 19136371
Respiration. 2009;77(3):344-50
pubmed: 19141987
Am J Respir Crit Care Med. 2009 Sep 15;180(6):506-12
pubmed: 19542481
Eur Respir J. 2010 Aug;36(2):292-300
pubmed: 20075059
Respiration. 2010;80(1):10-8
pubmed: 20234126
Thorax. 2010 Jun;65(6):499-504
pubmed: 20522846
Chest. 2011 Aug;140(2):331-342
pubmed: 21273294
Respir Res. 2011 Mar 22;12:33
pubmed: 21426563
Respir Med. 2011 Dec;105(12):1846-52
pubmed: 21803556
BMC Public Health. 2011 Aug 05;11:624
pubmed: 21819591
Int J Chron Obstruct Pulmon Dis. 2011;6:511-9
pubmed: 22069362
Chest. 2012 Aug;142(2):338-346
pubmed: 22281798
Respir Med. 2013 Jun;107(6):834-40
pubmed: 23514950
Thorax. 2013 Oct;68(10):962-3
pubmed: 23604460
Respir Res. 2013 Oct 30;14:115
pubmed: 24229341
Int J Epidemiol. 2014 Feb;43(1):69-77
pubmed: 24585853
Am J Respir Crit Care Med. 2015 Aug 1;192(3):295-306
pubmed: 26020495
Am J Respir Crit Care Med. 2015 Oct 15;192(8):924-33
pubmed: 26161676
Chest. 2016 Jan;149(1):238-51
pubmed: 26356330
J Korean Med Sci. 2015 Oct;30(10):1459-65
pubmed: 26425043
Ann Am Thorac Soc. 2015 Dec;12(12):1788-95
pubmed: 26524488
Am J Respir Crit Care Med. 2016 Apr 1;193(7):727-35
pubmed: 26540012
Medicine (Baltimore). 2015 Nov;94(47):e2089
pubmed: 26632722
BMC Med. 2018 Oct 4;16(1):178
pubmed: 30285854